0.2581
price down icon20.31%   -0.0658
after-market Dopo l'orario di chiusura: .26 0.0019 +0.74%
loading
Precedente Chiudi:
$0.3239
Aprire:
$0.315
Volume 24 ore:
2.01M
Relative Volume:
1.16
Capitalizzazione di mercato:
$66.39M
Reddito:
$175.04M
Utile/perdita netta:
$-44.52M
Rapporto P/E:
-1.4339
EPS:
-0.18
Flusso di cassa netto:
$-56.05M
1 W Prestazione:
+25.29%
1M Prestazione:
-46.67%
6M Prestazione:
-72.86%
1 anno Prestazione:
-80.88%
Intervallo 1D:
Value
$0.25
$0.32
Intervallo di 1 settimana:
Value
$0.1951
$0.3301
Portata 52W:
Value
$0.1951
$1.48

Adaptimmune Therapeutics Plc Adr Stock (ADAP) Company Profile

Name
Nome
Adaptimmune Therapeutics Plc Adr
Name
Telefono
44 1235 430000
Name
Indirizzo
60 JUBILEE AVENUE, ABINGDON, OXFORDSHIRE
Name
Dipendente
506
Name
Cinguettio
@Adaptimmune
Name
Prossima data di guadagno
2025-03-21
Name
Ultimi documenti SEC
Name
ADAP's Discussions on Twitter

Confronta ADAP con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ADAP
Adaptimmune Therapeutics Plc Adr
0.2581 66.39M 175.04M -44.52M -56.05M -0.18
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Adaptimmune Therapeutics Plc Adr Stock (ADAP) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-07-30 Iniziato H.C. Wainwright Buy
2024-05-30 Iniziato Scotiabank Sector Outperform
2023-03-24 Iniziato Bryan Garnier Buy
2023-01-03 Aggiornamento Guggenheim Neutral → Buy
2022-11-09 Aggiornamento Mizuho Neutral → Buy
2021-05-28 Iniziato Barclays Underweight
2020-04-22 Iniziato Mizuho Neutral
2019-08-02 Downgrade Guggenheim Buy → Neutral
2019-05-31 Iniziato ROTH Capital Buy
2019-05-30 Ripresa Citigroup Buy
2019-05-07 Downgrade SVB Leerink Outperform → Mkt Perform
2017-03-17 Iniziato Wells Fargo Market Perform
2016-10-24 Downgrade BofA/Merrill Neutral → Underperform
2016-09-30 Iniziato Raymond James Outperform
2016-02-25 Iniziato Citigroup Buy
2015-06-01 Iniziato BofA/Merrill Neutral
2015-06-01 Iniziato Guggenheim Buy
2015-06-01 Iniziato Leerink Partners Outperform
Mostra tutto

Adaptimmune Therapeutics Plc Adr Borsa (ADAP) Ultime notizie

pulisher
Apr 02, 2025

Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Today’s Hot Stock - stocksregister.com

Apr 02, 2025
pulisher
Apr 01, 2025

H.C. Wainwright cuts Adaptimmune stock target to $3, maintains Buy By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

H.C. Wainwright cuts Adaptimmune stock target to $3, maintains Buy - Investing.com India

Apr 01, 2025
pulisher
Mar 26, 2025

Guggenheim cuts Adaptimmune target to $1.75, maintains Buy By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Guggenheim cuts Adaptimmune target to $1.75, maintains Buy - Investing.com India

Mar 26, 2025
pulisher
Mar 24, 2025

Adaptimmune Therapeutics Amends Loan Agreement - Investing.com India

Mar 24, 2025
pulisher
Mar 21, 2025

Scotiabank cuts Adaptimmune price target to $1.40, keeps rating By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

Scotiabank cuts Adaptimmune price target to $1.40, keeps rating - Investing.com

Mar 21, 2025
pulisher
Mar 20, 2025

Mizuho maintains Outperform on Adaptimmune, price target $1.50 By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

Mizuho maintains Outperform on Adaptimmune, price target $1.50 - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

Earnings call transcript: Adaptimmune Q4 2024 targets $25M sales in 2025 - Investing.com

Mar 20, 2025
pulisher
Mar 06, 2025

Adaptimmune Therapeutics PLC Sponsored ADR to Host Earnings Call - ACCESS Newswire

Mar 06, 2025
pulisher
Feb 25, 2025

LAG-3 Immunotherapies Market Set for Rapid Growth in the Coming 10 Years Across the 7MM as Next-Generation Therapies Advance | DelveInsight - GlobeNewswire Inc.

Feb 25, 2025
pulisher
Feb 25, 2025

Analysts Recommend Holding Your Position In Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) - Stocks Register

Feb 25, 2025
pulisher
Feb 19, 2025

Investing in Adaptimmune Therapeutics Plc ADR (ADAP) Is Getting More Attractive - Knox Daily

Feb 19, 2025
pulisher
Feb 12, 2025

Potential Price Increase for Coterra Energy Inc (CTRA) After Recent Insider Activity - Knox Daily

Feb 12, 2025
pulisher
Feb 12, 2025

Taking a Closer Look At Dollar Tree Inc (DLTR) Following Its Recent Trade - Knox Daily

Feb 12, 2025
pulisher
Feb 12, 2025

A Guide To The Risks Of Investing In Agilon Health Inc (AGL) - Knox Daily

Feb 12, 2025
pulisher
Feb 11, 2025

Daily Progress: Quanterix Corp (QTRX) Drop -3.57, Closing at 7.83 - The Dwinnex

Feb 11, 2025
pulisher
Feb 08, 2025

Following A 4.11% Weekly Incline, Is It Still A Buy For Amylyx Pharmaceuticals Inc (NASDAQ: AMLX)? - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 08, 2025

Should Outset Medical Inc (NASDAQ: OM) Rally After -544.44% Drop From High? - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 08, 2025

Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Stock Falling -5.24% Over A Month – Any Room For Its Value To Rise? – Marketing Sentinel - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 08, 2025

BioVie Inc (NASDAQ: BIVI): How Can A Stock Be Down -4.00% Year To Date, But Still Loser - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 07, 2025

Adaptimmune Therapeutics Plc ADR (ADAP) Stock: A Closer Look at the Moving Averages - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

SM Energy Co (SM): A Technical Analysis - The News Heater

Feb 07, 2025
pulisher
Feb 04, 2025

Adaptimmune Therapeutics Plc ADR (ADAP)’s stock price in review: A technical analysis - US Post News

Feb 04, 2025
pulisher
Feb 04, 2025

Quarterly Snapshot: Quick and Current Ratios for Adaptimmune Therapeutics Plc ADR (ADAP) - The Dwinnex

Feb 04, 2025
pulisher
Jan 17, 2025

Adaptimmune therapeutics COO sells shares worth $3,243 - Investing.com India

Jan 17, 2025
pulisher
Jan 17, 2025

Adaptimmune therapeutics' chief medical officer sells $3,243 in stock By Investing.com - Investing.com South Africa

Jan 17, 2025
pulisher
Jan 17, 2025

Adaptimmune therapeutics' chief medical officer sells $3,243 in stock - Investing.com India

Jan 17, 2025
pulisher
Jan 17, 2025

Adaptimmune therapeutics COO sells shares worth $3,243 By Investing.com - Investing.com South Africa

Jan 17, 2025
pulisher
Jan 16, 2025

Adaptimmune therapeutics COO William Bertrand sells $11,360 in shares - Investing.com India

Jan 16, 2025
pulisher
Jan 15, 2025

Adaptimmune therapeutics' chief medical officer sells $12,920 in shares - Investing.com

Jan 15, 2025
pulisher
Jan 15, 2025

Adaptimmune's chief commercial officer sells $7,467 in shares - Investing.com

Jan 15, 2025
pulisher
Dec 23, 2024

AST SpaceMobile Inc Still Hasn’t Convinced Analysts? - Stocks Register

Dec 23, 2024
pulisher
Dec 23, 2024

These Numbers Show Just How Powerful Standard Lithium Ltd (AMEX: SLI) Stock ‎Is - Stocks Register

Dec 23, 2024
pulisher
Dec 23, 2024

What Did We Note About Insider Trading At Lithium Americas Corp (NewCo) (NYSE: LAC)? - Stocks Register

Dec 23, 2024
pulisher
Dec 23, 2024

Workhorse Group Inc (NASDAQ: WKHS) Could Pass $3.5 In One Year Stock Forecast - Stocks Register

Dec 23, 2024
pulisher
Dec 23, 2024

Barnes & Noble Education Inc (NYSE: BNED) -10.53% Decline Turns Investors Away - Stocks Register

Dec 23, 2024
pulisher
Dec 23, 2024

Applied Digital Corporation (NASDAQ: APLD) Could Pass $10 In One Year Stock Forecast - Stocks Register

Dec 23, 2024
pulisher
Dec 23, 2024

Asana Inc (NYSE: ASAN) Up 15.57% This Year: What Is Going To Happen Next - Stocks Register

Dec 23, 2024
pulisher
Dec 16, 2024

Adaptimmune's SWOT analysis: TCR-T pioneer faces challenges in stock outlook - Investing.com

Dec 16, 2024
pulisher
Dec 04, 2024

Adaptimmune's SWOT analysis: TCR-T therapy pioneer faces challenges post-FDA nod - Investing.com

Dec 04, 2024
pulisher
Dec 02, 2024

Royal Dutch Shell Plc ADR (SHEL-N) QuotePress Release - The Globe and Mail

Dec 02, 2024
pulisher
Nov 27, 2024

Mizuho lowers Adaptimmune price target by 50%, citing pipeline shifts and cost cuts - Investing.com

Nov 27, 2024
pulisher
Nov 18, 2024

EyePoint Pharmaceuticals Inc (NASDAQ: EYPT)’s Stock Reduces -12.58%, Making It A Good Investment - Stocks Register

Nov 18, 2024
pulisher
Nov 18, 2024

Analysts Predict Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) To Loss -577.97% From Current Levels. - Stocks Register

Nov 18, 2024
pulisher
Nov 14, 2024

Earnings call: Adaptimmune outlines new strategy amid Tecelra launch By Investing.com - Investing.com South Africa

Nov 14, 2024
pulisher
Nov 14, 2024

Adaptimmune stock holds Buy rating with lower target amid Q3 revenue outperformance - Investing.com

Nov 14, 2024
pulisher
Nov 05, 2024

ADAPAdaptimmune Therapeutics plc American Depositary Shares Latest Stock News & Market Updates - StockTitan

Nov 05, 2024
pulisher
Nov 01, 2024

Adaptimmune faces Nasdaq delisting over share price - Investing.com India

Nov 01, 2024

Adaptimmune Therapeutics Plc Adr Azioni (ADAP) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Capitalizzazione:     |  Volume (24 ore):